Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Intangibles (2023 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Intangibles for 3 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Intangibles fell 90.69% year-over-year to $6.4 million, compared with a TTM value of $6.4 million through Dec 2025, down 90.69%, and an annual FY2025 reading of $6.4 million, down 90.69% over the prior year.
  • Intangibles was $6.4 million for Q4 2025 at Zevra Therapeutics, down from $6.7 million in the prior quarter.
  • Across five years, Intangibles topped out at $69.2 million in Q4 2023 and bottomed at $2.0 million in Q2 2024.
  • Average Intangibles over 3 years is $31.9 million, with a median of $6.7 million recorded in 2025.
  • Peak annual rise in Intangibles hit 236.85% in 2025, while the deepest fall reached 90.69% in 2025.
  • Year by year, Intangibles stood at $69.2 million in 2023, then dropped by 0.34% to $69.0 million in 2024, then crashed by 90.69% to $6.4 million in 2025.
  • Business Quant data shows Intangibles for ZVRA at $6.4 million in Q4 2025, $6.7 million in Q3 2025, and $69.0 million in Q4 2024.